Success Metrics

Clinical Success Rate
50.0%

Based on 2 completed trials

Completion Rate
50%(2/4)
Active Trials
2(33%)
Results Posted
100%(2 trials)
Terminated
2(33%)

Phase Distribution

Ph phase_3
3
50%
Ph phase_2
2
33%
Ph phase_4
1
17%

Phase Distribution

0

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
3(50.0%)
Phase 4Post-market surveillance
1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(2)
Terminated(2)

Detailed Status

Terminated2
Completed2
Recruiting1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
50.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (33.3%)
Phase 33 (50.0%)
Phase 41 (16.7%)

Trials by Status

terminated233%
recruiting117%
active_not_recruiting117%
completed233%

Recent Activity

2 active trials
Showing 5 of 6
recruitingphase_3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

NCT06079879
active_not_recruitingphase_3

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

NCT04285086
terminatedphase_2

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

NCT03123588
terminatedphase_2

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

NCT02962388
completedphase_4

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

NCT00202644
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06079879Phase 3

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Recruiting
NCT04285086Phase 3

Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance

Active Not Recruiting
NCT03123588Phase 2

Phase 2 Study of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

Terminated
NCT02962388Phase 2

The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line

Terminated
NCT00202644Phase 4

A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients

Completed
NCT01065038Phase 3

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6